Chlorambucil
- Generic Name
- Chlorambucil
- Brand Names
- Leukeran
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19Cl2NO2
- CAS Number
- 305-03-3
- Unique Ingredient Identifier
- 18D0SL7309
- Background
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
- Indication
For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Indolent Lymphoma, Lymphoma, Lymphoma, Diffuse, MALT Lymphoma, Mantle Cell Lymphoma (MCL), Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Waldenström's Macroglobulinemia (WM), Giant follicular lymphoma
- Associated Therapies
- -
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 147
- Registration Number
- NCT01109264
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 357
- Registration Number
- NCT01056510
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
- Conditions
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01010061
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 450
- Registration Number
- NCT00910910
- Locations
- 🇺🇸
Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States
🇧🇪Hopital de Jolimont, Haine-Saint Paul, Belgium
🇧🇪CHU Mont -Godinne, Yvoir, Belgium
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00738374
- Locations
- 🇮🇹
Ospedale Cardarelli; Divisione Di Ematologia, Napoli, Campania, Italy
🇮🇹A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy
🇮🇹Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma
- Conditions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Taunton and Somerset Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT00608374
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇬🇧Bradford Royal Infirmary, Bradford, England, United Kingdom
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- French Study Group on Chronic Lymphoid Leukemia
- Target Recruit Count
- 414
- Registration Number
- NCT00566332
- Locations
- 🇫🇷
Hôpital La Pitié-Salpêtrière. 47-83 Bd de l'hôpital, Paris, France
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT00532129
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 358
- Registration Number
- NCT00417014
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.